Long-term outcomes of PD-1 inhibitors plus chemotherapy as first-line treatment for advanced HER2-negative gastric cancer: an updated systematic review and meta-analysis.
[INTRODUCTION] This meta-analysis was designed to compare the long-term outcomes of first-line programmed cell death protein 1 (PD-1) inhibitors plus chemotherapy versus chemotherapy in patients with
- p-value P<0.01
- 95% CI 0.89 to 0.93
- HR 0.91
- RR 1.22
- 연구 설계 meta-analysis
APA
Tong J, Zhou S, et al. (2025). Long-term outcomes of PD-1 inhibitors plus chemotherapy as first-line treatment for advanced HER2-negative gastric cancer: an updated systematic review and meta-analysis.. Frontiers in immunology, 16, 1651176. https://doi.org/10.3389/fimmu.2025.1651176
MLA
Tong J, et al.. "Long-term outcomes of PD-1 inhibitors plus chemotherapy as first-line treatment for advanced HER2-negative gastric cancer: an updated systematic review and meta-analysis.." Frontiers in immunology, vol. 16, 2025, pp. 1651176.
PMID
41341592
Abstract
[INTRODUCTION] This meta-analysis was designed to compare the long-term outcomes of first-line programmed cell death protein 1 (PD-1) inhibitors plus chemotherapy versus chemotherapy in patients with advanced HER2-negative gastric cancer (GC).
[MATERIALS AND METHODS] Four databases (PubMed, Embase, Web of Science, and the Cochrane Library) were searched for randomized controlled trials (RCTs) comparing first-line PD-1 inhibitors plus chemotherapy to chemotherapy in patients with advanced HER2-negative GC. The search was conducted from the databases establishment to October 11, 2025. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), treatment-related adverse events (TRAEs), and Grade≥3 TRAEs were subjected to meta-analyses.
[RESULTS] Six RCTs were included in the meta-analysis. The meta-analysis included a group of 6038 patients diagnosed with untreated advanced HER2-negative GC. Within this cohort, 3026 patients were administered first-line PD-1 inhibitors together with chemotherapy, while 3012 patients received first-line chemotherapy alone. Compared with chemotherapy, first-line PD-1 inhibitors plus chemotherapy yielded superior OS (HR = 0.91; 95% CI 0.89 to 0.93; P<0.01), PFS (HR = 0.89, 95%CI 0.87 to 0.91 P<0.01), and ORR (RR = 1.22, 95% CI, 1.16 to 1.29, P<0.01). With regards to safety, first-line PD-1 inhibitors plus chemotherapy exhibited a greater likelihood of encountering TRAEs (RR = 1.02, 95% CI: 1.00 to 1.04, P = 0.03) and Grade≥3 TRAEs (RR = 1.16, 95% Cl: 1.08 to 1.25, P<0.01) in comparison to chemotherapy.
[CONCLUSIONS] Compared with chemotherapy alone, PD-1 inhibitors plus chemotherapy as first-line therapy provided improved OS, PFS, and ORR. Furthermore, the heightened efficacy of PD-1 inhibitors plus chemotherapy was accompanied by a rise in TRAEs and Grade≥3 TRAEs.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/, identifier CRD420251015248.
[MATERIALS AND METHODS] Four databases (PubMed, Embase, Web of Science, and the Cochrane Library) were searched for randomized controlled trials (RCTs) comparing first-line PD-1 inhibitors plus chemotherapy to chemotherapy in patients with advanced HER2-negative GC. The search was conducted from the databases establishment to October 11, 2025. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), treatment-related adverse events (TRAEs), and Grade≥3 TRAEs were subjected to meta-analyses.
[RESULTS] Six RCTs were included in the meta-analysis. The meta-analysis included a group of 6038 patients diagnosed with untreated advanced HER2-negative GC. Within this cohort, 3026 patients were administered first-line PD-1 inhibitors together with chemotherapy, while 3012 patients received first-line chemotherapy alone. Compared with chemotherapy, first-line PD-1 inhibitors plus chemotherapy yielded superior OS (HR = 0.91; 95% CI 0.89 to 0.93; P<0.01), PFS (HR = 0.89, 95%CI 0.87 to 0.91 P<0.01), and ORR (RR = 1.22, 95% CI, 1.16 to 1.29, P<0.01). With regards to safety, first-line PD-1 inhibitors plus chemotherapy exhibited a greater likelihood of encountering TRAEs (RR = 1.02, 95% CI: 1.00 to 1.04, P = 0.03) and Grade≥3 TRAEs (RR = 1.16, 95% Cl: 1.08 to 1.25, P<0.01) in comparison to chemotherapy.
[CONCLUSIONS] Compared with chemotherapy alone, PD-1 inhibitors plus chemotherapy as first-line therapy provided improved OS, PFS, and ORR. Furthermore, the heightened efficacy of PD-1 inhibitors plus chemotherapy was accompanied by a rise in TRAEs and Grade≥3 TRAEs.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/, identifier CRD420251015248.
MeSH Terms
Humans; Stomach Neoplasms; Erb-b2 Receptor Tyrosine Kinases; Antineoplastic Combined Chemotherapy Protocols; Programmed Cell Death 1 Receptor; Immune Checkpoint Inhibitors; Treatment Outcome; Randomized Controlled Trials as Topic
같은 제1저자의 인용 많은 논문 (5)
- Benzo[a]pyrene promotes gastric cancer progression via activation of the Correa cascade through modulation of the STAT3-TP53-MMP9 molecular axis.
- p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer.
- Retraction: Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway.
- CCL22 and CCL26 are potential biomarkers for predicting distant metastasis in thyroid carcinoma.
- Adipose-derived mesenchymal stem cells formed acinar-like structure when stimulated with breast epithelial cells in three-dimensional culture.